On April 29, Gilead Sciences announced that the experimental drug ridacive may help patients with new coronary pneumonia recover faster from infection.
In response, the US Food and Drug Administration (FDA) may announce an emergency use authorization for redoxir.
According to a senior executive in the New York Times on April 29, the authorization may be launched as soon as possible. At present, the US FDA has not approved any drugs to treat the new coronavirus.
In a statement released to CNN, the US Food and Drug Administration stated that they are negotiating with Gilead Science Provide this medicine to patients.
US Food and Drug Administration spokesperson Michael Felberbaum said in a statement: “FDA is committed to accelerating the development and use of potential new coronary pneumonia treatments Germany discusses how to provide reduxil to patients as soon as possible under appropriate circumstances. “
On April 29, Gilead Scientific announced Two good news:
One is that the clinical trial from the National Institutes of Health (NIH) has reached the main end point and the data is positive; the second is the announcement of Gilead The open-label phase III clinical trial showed that patients receiving 5-day course of reduxil were similar to those receiving 10-day course of reduxil, and more than half of them achieved clinical recovery.
On the same day, Anthony Fudge, director of the National Institute of Allergy and Infectious Diseases and chief infectious disease expert, also expressed that the early treatment of new coronary pneumonia patients with redcivir The test results have good news, the data shows that the drug can significantly shorten the treatment time of new coronary pneumonia.
According to CNBC ’s report that day, Foch told the White House reporter that he was informed that the early trial data of ridxivir showed that the drug was used to treat patients with new coronary pneumonia. “There is a clear positive effect in shortening the recovery time.”
The results of this trial showed that patients receiving Radecivir recovered 31% faster than those receiving placebo, and the recovery time was shortened from 15 days to 11 day.
Fochi called the results of this experiment” very important “and compared it to the” moment of hope “in 1986.
The results of Desivir ’s clinical trials in China are not so optimistic.
On the evening of April 29, Beijing time, the website of the internationally renowned medical journal “The Lancet” was published by China The results of the clinical trial of reduxilvir conducted by the team. The results of the study showed that no statistically significant clinical benefit was observed in the combination of redoxivir and standard therapy compared with standard therapy.
Professor Cao Bin of the China-Japan Friendship Hospital and Capital Medical University, who was in charge of the study, said:” This trial found that although Ridesivir is safe and well tolerated, it is comparable to placebo There are no significant benefits. ”
In response to the question that the conclusions of the clinical trials between China and the United States are quite different, Professor Cao Bin, the head of the clinical trial of Red West China responded to the surging news reporters:” This These are two different studies with different evaluation criteria. “
” The standard used by the US NIH at the beginning was the same as ours, but it was later changed. “Bao Cao told the surging news reporter.
At present, New Coronary Pneumonia has not been proven to be effective.
div> Ridexivir was once considered to be the most promising drug against the new coronavirus and was developed by Gilead Scientific, headquartered in California, USA. Redsivir is already treating SARS and Middle East Respiratory Syndrome (MERS) ) Has shown some hope in the treatment, both of these diseases are caused by coronavirus.
At present, more than one million cases of new coronary pneumonia have been diagnosed in the United States. The demand for therapeutic drugs is obviously the most urgent.